17th Consecutive Quarter of Record Revenue
IRADIMED achieved its 17th consecutive quarter of record revenue, with Q3 2025 revenue surpassing Q3 2024 by 16%, reaching $21.2 million.
Strong Growth in Product Lines
The 3860 MRI IV pump grew 20% year-over-year in Q3, and MRI patient monitor shipments grew by 16%. Gross profit margin was 78%, with earnings per share increasing by 8% from Q3 2024.
Positive Outlook for 3870 MRI IV Pump
The new 3870 MRI IV pump, expected to increase revenue significantly, is anticipated to penetrate new markets and replace older models. A price increase of 10% to 14% is planned, with a target to sell 2,000 channels annually.
Raised Financial Guidance for 2025
Revenue guidance for 2025 increased to $82.5 million to $83.5 million, with GAAP EPS expected to be $1.68 to $1.72, up from previous estimates.
Strong Financials and Cash Position
Net income increased by 12% to $5.6 million, with cash and cash equivalents rising to $56.5 million. Free cash flow was $5.7 million for the quarter.